9,387 Matching Annotations
  1. Jan 2021
    1. Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., Berghmans, P.-J., Kimmel, M., Van Damme, P., de Hoon, J., Smith, W., Stephenson, K. E., De Rosa, S. C., Cohen, K. W., McElrath, M. J., … Schuitemaker, H. (2021). Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMoa2034201

    1. Jo Maugham QC [@jolyonMaugham] (2020, August) Calling on retired lawyers! Law students! Bored lawyers! We at @GoodLawProject need your help with some research... we are working on what will be (well, if we win it) seminal litigation to establish the precautionary principle as a freestanding part of E&W common law! Twitter. Retrieved from: https://twitter.com/JolyonMaugham/status/1296092565075369984

  2. Dec 2020
    1. Bu Experts {@BU Experts} (2020) How can we navigate daily life during the pandemic? #Publichealth expert & epidemiologist @EpiEllie will be on @reddit_AMA this Thursday (8/27) at 12pm ET to answer all of your #COVID19-related questions. She'll discuss how to safely see friends and family, travel & more. @BUSPH. Twitter. Retrieved from: https://twitter.com/BUexperts/status/1297932614909792258

    1. Emily. J. Miller. - FDA {@FDASpox} (2020) Convalescent plasma has shown to be beneficial for 35% of patients. This risk reduction figure - shown in chart below - is from @MayoClinic data from expanded access program that was analyzed by FDAA for the emergency use authorization announced today. Twitter. Retrieved from: https://twitter.com/FDASpox/status/1297706985039835136

    1. Stuaert Rtchie [@StuartJRitchie] (2020) This encapsulates the problem nicely. Sure, there’s a paper. But actually read it & what do you find? p-values mostly juuuust under .05 (a red flag) and a sample size that’s FAR less than “25m”. If you think this is in any way compelling evidence, you’ve totally been sold a pup. Twitter. Retrieved from:https://twitter.com/StuartJRitchie/status/1305963050302877697

    1. Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., … Zuidewind, P. (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)32661-1

  3. Nov 2020